Peter Muir

Peter Muir

Auto-generated profile, based on publicly available information

Peter Muir

UK Health Security Agency Clinical Network Laboratory, Southmead Hospital, Bristol, UK

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2020 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
DADavid T. Arnold
David T. Arnold
FHFergus W. Hamilton
Fergus W. Hamilton
TMTim Morris
Tim Morris
TSTim Suri
Tim Suri
AMAnna Morley
Anna Morley
NMNick A. Maskell
Nick A. Maskell
Pleural empyema represents a significant healthcare burden due to extended hospital admissions and potential requirement for surgical intervention. This study aimed to assess changes in incidence and management of pleural empyema in England over the past 10 years and the potential impact of influenza on rates.Hospital Episode Statistics data were used to identify patients admitted to English hospitals with pleural empyema between 2008 and 2018. Linear regression was used to analyse the relationship between empyema rates and influenza incidence recorded by Public Health England. The relationship between influenza and empyema was further explored using serological data from a prospective cohort study of patients presenting with pleural empyema.Between April 2008 and March 2018 there were 55 530 patients admitted with pleural empyema. There was male predominance (67%versus33%), which increased with age. Cases have increased significantly from 4447 in 2008 to 7268 in 2017. Peaks of incidence correlated moderately with rates of laboratory-confirmed influenza in children and young adults (r=0.30). For nine of the 10 years studied, the highest annual point incidence of influenza coincided with the highest admission rate for empyema (with a 2-week lag). In a cohort study of patients presenting to a single UK hospital with pleural empyema/infection, 24% (17 out of 72) had serological evidence of recent influenza infection, compared to 7% in seasonally matched controls with simple parapneumonic or cardiogenic effusions (p<0.001).Rates of empyema admissions in England have increased steadily with a seasonal variation that is temporally related to influenza incidence. Patient-level serological data from a prospective study support the hypothesis that influenza may play a pathogenic role in empyema development.

1 October 2001 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
JBJustin W. A. Bendig
Justin W. A. Bendig
POPatrick S. O'Brien
Patrick S. O'Brien
PMPeter Muir
Peter Muir
We describe the development of a coxsackievirus A16 (CVA16) serotype-specific PCR which correctly differentiated between CVA16 and other enterovirus serotypes of both laboratory isolates and clinical specimens. The assay will be useful for monitoring CVA16 outbreaks and studying the disease association, epidemiology, and evolution of this common enterovirus serotype.

20 May 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SASamantha Elizabeth Abbs
Samantha Elizabeth Abbs
LALindsay Armstrong-Buisseret
Lindsay Armstrong-Buisseret
KEKathy Eastwood
Kathy Eastwood
SGStephen Granier
Stephen Granier
ALAthene Lane
Athene Lane
AHAlastair D Hay
Alastair D Hay
Antibiotics are prescribed for over 50% of respiratory tract infections in primary care, despite good evidence of there being no benefit to the patient, and evidence of over prescribing driving microbial resistance. The high treatment rates are attributed to uncertainty regarding microbiological cause and clinical prognosis. Point-of-care-tests have been proposed as potential antibiotic stewardship tools, with some providing microbiological results in 15 minutes. However, there is little research on their impact on antibiotic use and clinical outcomes in primary care. This is a multi-centre, individually randomised controlled trial with mixed-methods investigation of microbial, behavioural and antibiotic mechanisms on outcomes in patients aged 12 months and over presenting to primary care in the UK with a suspected respiratory tract infection, where the clinician and/or patient thinks antibiotic treatment may be, or is, necessary. Once consented, all participants are asked to provide a combined nose and throat swab sample and randomised to have a rapid microbiological point-of-care-test or no point-of-care-test. For intervention patients, clinicians review the result of the test, before contacting the patient to finalise treatment. Treatment decisions are made as per usual care in control group patients. The primary outcome is whether an antibiotic is prescribed at this point. All swab samples are sent to the central laboratory for further testing. Patients are asked to complete a diary to record the severity and duration of symptoms until resolution or day 28, and questionnaires at 2 months about their beliefs and intention to consult for similar future illnesses. Primary care medical records are also reviewed at 6-months to collect further infection consultations, antibiotic prescribing and hospital admissions. The trial aims to recruit 514 patients to achieve 90% power with 5% significance to detect a 15% absolute reduction in antibiotic prescribing. Qualitative interviews are being conducted with approximately 20 clinicians and 30 participants to understand any changes in beliefs and behaviour resulting from the point-of-care-test and generate attributes for clinician and patient discrete choice experiments. This trial will provide evidence of efficacy, acceptability and mechanisms of action of a rapid microbiological point-of-care test on antibiotic prescribing and patient symptoms in primary care. ISRCTN16039192, prospectively registered on 08/11/2022.

18 May 2015 in Sexually Transmitted Infections
Verified
Journal Article
Open access
PDF file
PHPatrick Horner
Patrick Horner
SISuzanne Ingle
Suzanne Ingle
KBKarla Blee
Karla Blee
PMPeter Muir
Peter Muir
HMHarald Moi
Harald Moi
Background Mycoplasma genitalium (MG) is an emerging important STI. Failure rates with azithromycin 1 g appear to be increasing. This may be due to the emergence of macrolide antimicrobial resistance as a consequence of extensive use of azithromycin 1 g. An extended regimen of azithromycin 500 mgs on day one then 250 mgs daily for 4 days (5 day regimen) was introduced in the 1990s for treatment of MG and has high efficacy rates (if no pre-existing macrolide resistance) and is less associated with induction of macrolide resistance. There are no comparative trials of the two regimens. Treatment of Mycoplasma genitalium Aim To undertake a meta-analysis of MG treatment studies using the two azithromycin regimens to determine which is more effective. Methods MG treatment studies were included if: patients were initially assessed for macrolide resistance genetic mutations, were treated with azithromycin 1 g or 5 days, and those who failed were again resistance genotyped. Sensitivity analyses included only patients without prior treatment. Results Five studies were identified. Compared to the 5 day regimen, azithromycin 1 g had higher failure risk (difference: 11.8%, 95% CI: 7.3%, 16.2%) and more developed macrolide resistance (risk difference: 11.8% (8.3%, 15.3%)). The 5 day regimen included 52 patients with prior doxycycline treatment. Sensitivity analysis showed a failure risk difference of 9.2% (0.9%, 17.5%). Resistance risk did not change. Conclusion Azithromycin 1 g is more likely to result in treatment failure and the development of macrolide antimicrobial resistance than 500 mgs on day one then 250 mgs daily for 4 days.

4 July 2020 in medRxiv
Verified
Preprint
Open access
PDF file
FHFergus Hamilton
Fergus Hamilton
PMPeter Muir
Peter Muir
MAMarie Attwood
Marie Attwood
ANAlan Noel
Alan Noel
BVBarry Vipond
Barry Vipond
DADavid T Arnold
David T Arnold
Objectives: To assess the performance (sensitivity and specificity) of the Abbott Architect SARS-CoV-2 IgG antibody assay across three clinical settings. Methods: Antibody testing was performed on three clinical cohorts of COVID-19 disease: hospitalised patients with PCR confirmation, hospitalized patients with a clinical diagnosis but negative PCR, and symptomatic healthcare workers (HCW’s). Pre-pandemic respiratory infection sera were tested as negative controls. The sensitivity of the assay was calculated at different time points (20 days, >42 days), and compared between cohorts. Results: Performance of the Abbot Architect SARS-CoV-2 assay varied significantly between cohorts. For PCR confirmed hospitalised patients (n = 114), early sensitivity was low: 20 days had negative results, generating a sensitivity of 85.1% (95%CI, 77.4% - 90.5%). All pre-pandemic sera were negative, a specificity of 100%. Seroconversion rates were similar for PCR positive and PCR negative hospitalised cases. Conclusions: The sensitivity of the Abbot Architect SARS-CoV-2 IgG assay increases over time, with sensitivity not peaking until 20 days post symptoms. Performance varied markedly by setting, with sensitivity significantly worse in symptomatic healthcare workers than in the hospitalised cohort. Clinicians, policymakers, and patients should be aware of the reduced sensitivity in this setting.

5 May 2022 in medRxiv
Verified
Preprint
Open access
PDF file
AHAlice Halliday
Alice Halliday
ALAnna E Long
Anna E Long
HBHolly E Baum
Holly E Baum
ATAmy C Thomas
Amy C Thomas
KSKathryn L Shelley
Kathryn L Shelley
AFAdam Finn
Adam Finn
Low-volume antibody assays can be used to track SARS-CoV-2 infection rates in settings where active testing for virus is limited and remote sampling is optimal. We developed 12 ELISAs detecting total or antibody isotypes to SARS-CoV-2 nucleocapsid, spike protein or its receptor binding domain (RBD), 3 anti-RBD isotype specific luciferase immunoprecipitation system (LIPS) assays and a novel Spike-RBD bridging LIPS total-antibody assay. We utilised pre-pandemic (n=984) and confirmed/suspected recent COVID-19 sera taken pre-vaccination rollout in 2020 (n=269). Assays measuring total antibody discriminated best between pre-pandemic and COVID-19 sera and were selected for diagnostic evaluation. In the blind evaluation, two of these assays (Spike Pan ELISA and Spike-RBD Bridging LIPS assay) demonstrated >97% specificity and >92% sensitivity for samples from COVID- 19 patients taken >21 days post symptom onset or PCR test. These assays offered better sensitivity for the detection of COVID-19 cases than a commercial assay which requires 100-fold larger serum volumes. This study demonstrates that low-volume in- house antibody assays can provide good diagnostic performance, and highlights the importance of using well-characterised samples and controls for all stages of assay development and evaluation. These cost-effective assays may be particularly useful for seroprevalence studies in low and middle-income countries.